WO2015155753A3 - Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique - Google Patents

Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique Download PDF

Info

Publication number
WO2015155753A3
WO2015155753A3 PCT/IB2015/056083 IB2015056083W WO2015155753A3 WO 2015155753 A3 WO2015155753 A3 WO 2015155753A3 IB 2015056083 W IB2015056083 W IB 2015056083W WO 2015155753 A3 WO2015155753 A3 WO 2015155753A3
Authority
WO
WIPO (PCT)
Prior art keywords
linkers
drugs
biological molecule
specific conjugation
cell
Prior art date
Application number
PCT/IB2015/056083
Other languages
English (en)
Other versions
WO2015155753A2 (fr
Inventor
Robert Yongxin Zhao
Robert Zhao
Original Assignee
Suzhou M-Conj Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou M-Conj Biotech Co., Ltd filed Critical Suzhou M-Conj Biotech Co., Ltd
Priority to PCT/IB2015/056083 priority Critical patent/WO2015155753A2/fr
Priority to JP2018506984A priority patent/JP6817288B2/ja
Priority to CA2991975A priority patent/CA2991975C/fr
Priority to CN201580082582.5A priority patent/CN108289964B/zh
Priority to CN202210788010.0A priority patent/CN115300640A/zh
Publication of WO2015155753A2 publication Critical patent/WO2015155753A2/fr
Publication of WO2015155753A3 publication Critical patent/WO2015155753A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouvelles séquences de liaison contenant un groupe succinique 2,3-disubstitué, ou un groupe fumarique ou maléique (trans (E)- ou cis (Z) butènedioïque) 2-monosubstitué, ou 2,3-disubstitué, pour la conjugaison d'au moins deux composés/agents cytotoxiques par séquence de liaison à une molécule de liaison cellulaire, au moyen d'une liaison par pontage de paires de thiols sur la molécule de liaison cellulaire de manière spécifique. L'invention concerne également des procédés de préparation de telles séquences de liaison, et d'utilisation de ces séquences de liaison pour la production de conjugués homogènes, ainsi que d'application de ces conjugués dans le traitement de cancers, d'infections et de maladies auto-immunes.
PCT/IB2015/056083 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique WO2015155753A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/IB2015/056083 WO2015155753A2 (fr) 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique
JP2018506984A JP6817288B2 (ja) 2015-08-10 2015-08-10 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
CA2991975A CA2991975C (fr) 2015-08-10 2015-08-10 Nouvelles sequences de liaison et leurs utilisation pour la conjugaison specifique de medicaments a une molecule biologique
CN201580082582.5A CN108289964B (zh) 2015-08-10 2015-08-10 新型连接体及其用于药物和生物分子的特异性偶联
CN202210788010.0A CN115300640A (zh) 2015-08-10 2015-08-10 新型连接体及其用于药物和生物分子的特异性偶联

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/056083 WO2015155753A2 (fr) 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique

Publications (2)

Publication Number Publication Date
WO2015155753A2 WO2015155753A2 (fr) 2015-10-15
WO2015155753A3 true WO2015155753A3 (fr) 2016-06-30

Family

ID=54288492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/056083 WO2015155753A2 (fr) 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique

Country Status (4)

Country Link
JP (1) JP6817288B2 (fr)
CN (2) CN108289964B (fr)
CA (1) CA2991975C (fr)
WO (1) WO2015155753A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7330515B2 (ja) * 2015-08-10 2023-08-22 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CA3209672A1 (fr) * 2016-02-04 2016-04-21 Hangzhou Dac Biotech Co., Ltd. Lieurs de conjugaison specifique, immunoconjugues specifiques de ceux-ci, procedes de fabrication et utilisations desdits conjugues de ceux-ci
CN106397226A (zh) * 2016-04-19 2017-02-15 福安药业集团宁波天衡制药有限公司 一种他莫昔芬的新制备方法
EP3445401A4 (fr) * 2016-04-20 2019-11-20 Hangzhou DAC Biotech Co, Ltd Dérivés de toxines d'amanites et leur conjugaison à une molécule de liaison cellulaire
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
CN116143678A (zh) * 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
EP3601346A1 (fr) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
IL301638B1 (en) 2017-09-29 2024-05-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
CR20200239A (es) 2017-12-01 2020-09-21 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados de este
WO2019109415A1 (fr) * 2017-12-04 2019-06-13 清华大学 Composé de dégradation ciblée de hmgcr et son application
CN109956972A (zh) * 2017-12-22 2019-07-02 四川科瑞德凯华制药有限公司 塞替派晶型i及其制备方法和用途
BR112020010405A2 (pt) * 2017-12-31 2020-11-24 Hangzhou Dac Biotech Co., Ltd compostos conjugado conectado à cadeia lateral e de conexão de cadeia lateral, cadeias laterais q1 e q2, d (estrutura de tubulisina), w, l1, l2, v1 e v2, agente/molécula de ligação de célula, célula de tumor, composição farmacêutica, e, agentes quimioterapêutico e sinergísticos
CN108586556B (zh) * 2018-01-17 2021-04-20 浙江海正药业股份有限公司 一种喷司他丁的晶型及其制备方法和用途
CN112867724B (zh) * 2018-07-23 2024-06-04 熙源安健医药(北京)有限公司 二膦酸盐药物缀合物
CA3108854C (fr) 2018-08-09 2022-02-15 Siemens Healthcare Diagnostics Inc. Composition d'une matiere premiere de bilirubine et son procede de preparation
SG11202103424UA (en) * 2018-10-12 2021-05-28 Hangzhou Dac Biotech Co Ltd Conjugation linkers containing 2,3-diaminosuccinyl group
WO2020081493A1 (fr) 2018-10-16 2020-04-23 Molecular Templates, Inc. Protéines de liaison pd-l1
CA3119956A1 (fr) 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Conjugue anticorps anti-cdh6-derive de pyrrolobenzodiazepine
MX2021006726A (es) * 2018-12-07 2021-09-23 Univ Oxford Innovation Ltd Enlazadores.
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020210689A1 (fr) * 2019-04-11 2020-10-15 Sony Corporation Médicaments polymères programmables
WO2020210694A1 (fr) * 2019-04-11 2020-10-15 Sony Corporation Médicaments polymères programmables
JP2022532342A (ja) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
CN110256313B (zh) * 2019-05-15 2021-01-29 江苏省原子医学研究所 一种光敏剂前药化合物及其制备方法和应用
CN114040779A (zh) * 2019-06-24 2022-02-11 杭州多禧生物科技有限公司 含支链连接子的细胞结合分子与细胞毒性剂的偶联物
CA3145050A1 (fr) 2019-06-29 2021-01-07 Robert Zhao Conjugue molecule de liaison cellulaire-derive de tubulysine et methode de preparation associee
CN110508029B (zh) * 2019-09-04 2022-01-28 武玉香 一种用于同时提取氟苯尼考、氯霉素、甲砜霉素的免疫亲和柱
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN115671119B (zh) * 2020-02-26 2023-11-10 上海科技大学 柯里拉京在抗冠状病毒中的应用
CN111393346B (zh) * 2020-06-02 2020-08-25 凯莱英生命科学技术(天津)有限公司 N-Boc-Dolaproine及Boc-Dap DCHA的合成方法
EP4208259A2 (fr) 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Anticorps anti-nectine-4 et leurs utilisations
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114478420A (zh) * 2020-11-13 2022-05-13 北京大学 多特异生物偶联连接臂及其合成方法
CN114605367B (zh) * 2020-12-03 2023-06-27 中国人民解放军军事科学院军事医学研究院 含香豆素的连接子及含该连接子的抗体偶联药物
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
CN112535678A (zh) * 2020-12-28 2021-03-23 烟台大学 连接曲妥珠单抗的美登素纳米粒组合物
CN112675305B (zh) * 2021-01-22 2023-05-23 中国科学院深圳先进技术研究院 用于肿瘤治疗的双亲性分子自组装纳米药物及制备方法和用途
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114106088A (zh) * 2021-04-28 2022-03-01 联宁（苏州）生物制药有限公司 基于溴甲基吡嗪的药物偶联物及adc
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2021362997A1 (en) * 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114533669B (zh) * 2022-01-18 2022-11-04 武汉大学 一种口腔护理组合物及其制备方法和应用
WO2024073106A1 (fr) * 2022-09-29 2024-04-04 Tract Pharmaceuticals, Inc. Composés et compositions utiles en tant qu'inhibiteurs de taps
CN116754760B (zh) * 2023-06-14 2024-01-26 之江实验室 2,4-二硝基苯酚(dnp)与抗体可控断裂偶联的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038159A2 (fr) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Conjugués ligand-médicament dr5
WO2014080251A1 (fr) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules
WO2014197854A1 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
WO2015113476A1 (fr) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 Conjugué de médicaments cytotoxiques et de ligands, son procédé de préparation et ses applications
WO2015151080A2 (fr) * 2015-07-04 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Conjugaison spécifique d'une molécule de liaison cellulaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL45594A (en) * 1973-11-12 1977-12-30 Stauffer Chemical Co Bis-substituted succinamides and their use as herbicides
SG11201402686UA (en) * 2011-12-05 2014-06-27 Igenica Inc Antibody-drug conjugates and related compounds, compositions, and methods
JP2015510877A (ja) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾
HUE061182T2 (hu) * 2012-07-12 2023-05-28 Hangzhou Dac Biotech Co Ltd Sejtkötõ molekulák konjugátumai citotoxikus szerekkel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038159A2 (fr) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Conjugués ligand-médicament dr5
WO2014080251A1 (fr) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules
WO2014197854A1 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
WO2015113476A1 (fr) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 Conjugué de médicaments cytotoxiques et de ligands, son procédé de préparation et ses applications
WO2015151080A2 (fr) * 2015-07-04 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Conjugaison spécifique d'une molécule de liaison cellulaire

Also Published As

Publication number Publication date
JP2018532695A (ja) 2018-11-08
CA2991975A1 (fr) 2015-10-15
CN108289964B (zh) 2022-08-12
CN108289964A (zh) 2018-07-17
WO2015155753A2 (fr) 2015-10-15
CA2991975C (fr) 2021-04-06
JP6817288B2 (ja) 2021-01-20
CN115300640A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
WO2015155753A3 (fr) Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique
PH12018501638A1 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
WO2015151081A3 (fr) Lieurs de pontage pour la conjugaison d'une molécule de liaison cellulaire
EP3949969A3 (fr) Composés benzazépine, conjugués et leurs utilisations
PH12019502278A1 (en) Conjugation of a cytotoxic drug with bis-linkage
ZA201903062B (en) Amanitin antibody conjugates
PH12019501056A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2019010222A3 (fr) Polynucléotides codant pour des molécules de fusion immunostimulantes et leurs utilisations
ZA201805336B (en) Amanitin conjugates
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12018501777A1 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2020056198A3 (fr) Composés de benzazépine substitués, conjugués et leurs utilisations
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2015151080A3 (fr) Conjugaison spécifique d'une molécule de liaison cellulaire
WO2019136180A3 (fr) Molécules d'acide nucléique hétéroduplex et leurs utilisations
WO2016147031A3 (fr) Nouveaux lieurs hydrophiles et conjugués ligand-médicament les comprenant
WO2018098269A3 (fr) Lieurs contenant des peptides pour des conjugués anticorps-médicament
MY195368A (en) A Conjugation Linker Containing 2,3-Diaminosuccinyl Group
PH12016501995A1 (en) Tubulysin derivatives
JOP20190155A1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
ZA202001747B (en) Psma-targeting amanitin conjugates
WO2017180789A3 (fr) Méthodes de traitement faisant intervenir des conjugués de chlorotoxine
MX2021007706A (es) Conjugados de agonistas de receptor de reconocimiento de patron.
MX2021001545A (es) Péptidos penetrantes celulares.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2991975

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018506984

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15776256

Country of ref document: EP

Kind code of ref document: A2